Aflibercept, with the CAS number 862111-32-8, is a recombinant fusion protein that acts as a vascular endothelial growth factor (VEGF) inhibitor. It is primarily used in the treatment of various eye diseases, such as age-related macular degeneration and diabetic macular edema, as well as certain cancers. Aflibercept functions by binding to VEGF-A, VEGF-B, and placental growth factor (PlGF), thereby preventing these factors from interacting with their receptors and inhibiting angiogenesis, which is the formation of new blood vessels. This mechanism helps to reduce abnormal blood vessel growth and leakage in the retina. The substance is administered via intravitreal injection, and its molecular structure consists of a portion derived from the extracellular domains of human VEGF receptors fused to the Fc region of human IgG1, enhancing its stability and half-life in circulation. Aflibercept is generally well-tolerated, but like all medications, it may have side effects, including ocular inflammation and increased intraocular pressure.

Aflibercept

862111-32-8: Aflibercept, with the CAS number 862111-32-8, is a recombinant fusion protein that acts as a vascular endothelial growth factor (VEGF) inhibitor. It is primarily used in the treatment of various eye diseases, such as age-related macular degeneration and diabetic macular edema, as well as certain cancers. Aflibercept functions by binding to VEGF-A, VEGF-B, and placental growth factor (PlGF), thereby preventing these factors from interacting with their receptors and inhibiting angiogenesis, which is the formation of new blood vessels. This mechanism helps to reduce abnormal blood vessel growth and leakage in the retina. The substance is administered via intravitreal injection, and its molecular structure consists of a portion derived from the extracellular domains of human VEGF receptors fused to the Fc region of human IgG1, enhancing its stability and half-life in circulation. Aflibercept is generally well-tolerated, but like all medications, it may have side effects, including ocular inflammation and increased intraocular pressure.

<p>Aflibercept has a wide range of applications in life science related research.</p>

<p>Recombinant protein against VEGF(A); binds placental growth factor (PIGF)</p>

CAS 862111-32-8

Aflibercept

Aflibercept

Ref: TM-T72974

Aflibercept - approx 40mg/ml solution

Ref: 3D-BA165580